
Sitagliptin (50mg) + Metformin (500mg)
Rayax Drug India
Sitagliptin 50mgPack Size
Strip of 15 tablets
Price
Save ₹152
that's 51% off!
Active composition
+1 more active ingredient
Sitagliptin inhibits DPP-4, increasing incretin levels, which stimulate insulin release and reduce glucagon secretion.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Istacare 50/500 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. The synergistic action of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Istacare 50/500 is typically prescribed as an adjunct to diet and exercise to improve blood sugar levels in adults inadequately controlled on metformin alone or in combination with other antidiabetic agents. It is important to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with metformin. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Dose adjustments may be necessary in patients with renal impairment. Istacare 50/500 should be used under medical supervision with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Istacare 50/500 Tablet during pregnancy is not available. Please consult your doctor.
Medical Advice
Istacare 50/500 Tablet should be used with caution in patients with kidney disease. Dose adjustment of Istacare 50/500 Tablet may be needed. Please consult your doctor. Use of Istacare 50/500 Tablet is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
Istacare 50/500 Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Istacare 50/500 Tablet

Sitagliptin (50mg) + Metformin (500mg)
Rayax Drug India
Sitagliptin 50mgPack Size
Strip of 15 tablets
Price
Save ₹152
that's 51% off!
Active composition
+1 more active ingredient
Sitagliptin inhibits DPP-4, increasing incretin levels, which stimulate insulin release and reduce glucagon secretion.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Istacare 50/500 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. The synergistic action of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Istacare 50/500 is typically prescribed as an adjunct to diet and exercise to improve blood sugar levels in adults inadequately controlled on metformin alone or in combination with other antidiabetic agents. It is important to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with metformin. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Dose adjustments may be necessary in patients with renal impairment. Istacare 50/500 should be used under medical supervision with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Istacare 50/500 Tablet during pregnancy is not available. Please consult your doctor.
Medical Advice
Istacare 50/500 Tablet should be used with caution in patients with kidney disease. Dose adjustment of Istacare 50/500 Tablet may be needed. Please consult your doctor. Use of Istacare 50/500 Tablet is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
Istacare 50/500 Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Istacare 50/500 Tablet













